These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 22577589)

  • 21. Modulation of toll-like receptors by insulin.
    Tilich M; Arora RR
    Am J Ther; 2011 Sep; 18(5):e130-7. PubMed ID: 21326087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treating atherosclerosis: the potential of Toll-like receptors as therapeutic targets.
    Cole JE; Mitra AT; Monaco C
    Expert Rev Cardiovasc Ther; 2010 Nov; 8(11):1619-35. PubMed ID: 21090937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toll-like receptors in health and disease.
    Wang K; Huang H; Zhan Q; Ding H; Li Y
    MedComm (2020); 2024 May; 5(5):e549. PubMed ID: 38685971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the toll-system in cardiovascular sciences.
    Földes G; von Haehling S; Jankowska EA; Anker SD
    Recent Pat Inflamm Allergy Drug Discov; 2007 Feb; 1(1):57-67. PubMed ID: 19075967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Revisiting Platelets and Toll-Like Receptors (TLRs): At the Interface of Vascular Immunity and Thrombosis.
    Hally K; Fauteux-Daniel S; Hamzeh-Cognasse H; Larsen P; Cognasse F
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32858930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toll-Like Receptors (TLRs): The Role in Tumor Progression.
    Shcheblyakov DV; Logunov DY; Tukhvatulin AI; Shmarov MM; Naroditsky BS; Gintsburg AL
    Acta Naturae; 2010 Jul; 2(3):21-9. PubMed ID: 22649649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of innate immune sensors, TLRs, and NALP3 in rheumatoid arthritis and osteoarthritis.
    Takakubo Y; Barreto G; Konttinen YT; Oki H; Takagi M
    J Long Term Eff Med Implants; 2014; 24(4):243-51. PubMed ID: 25747027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endogenous inflammatory molecules engage Toll-like receptors in cardiovascular disease.
    Ionita MG; Arslan F; de Kleijn DP; Pasterkamp G
    J Innate Immun; 2010; 2(4):307-15. PubMed ID: 20431283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toll-like receptors and atherosclerosis: key contributors in disease and health?
    Mullick AE; Tobias PS; Curtiss LK
    Immunol Res; 2006; 34(3):193-209. PubMed ID: 16891671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toll-like receptors as potential therapeutic targets in cardiac dysfunction.
    Hofmann U; Ertl G; Frantz S
    Expert Opin Ther Targets; 2011 Jun; 15(6):753-65. PubMed ID: 21385118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Engagement of specific innate immune signaling pathways during Porphyromonas gingivalis induced chronic inflammation and atherosclerosis.
    Gibson FC; Ukai T; Genco CA
    Front Biosci; 2008 Jan; 13():2041-59. PubMed ID: 17981690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of endothelial function by Toll like receptors.
    Salvador B; Arranz A; Francisco S; Córdoba L; Punzón C; Llamas MÁ; Fresno M
    Pharmacol Res; 2016 Jun; 108():46-56. PubMed ID: 27073018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of toll-like receptors in cardiovascular diseases.
    Vallejo JG
    Clin Sci (Lond); 2011 Jul; 121(1):1-10. PubMed ID: 21413930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Injury to allografts: innate immune pathways to acute and chronic rejection.
    Land WG
    Saudi J Kidney Dis Transpl; 2005; 16(4):520-39. PubMed ID: 18202507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of disease: Toll-like receptors in cardiovascular disease.
    Frantz S; Ertl G; Bauersachs J
    Nat Clin Pract Cardiovasc Med; 2007 Aug; 4(8):444-54. PubMed ID: 17653117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics.
    Gao W; Xiong Y; Li Q; Yang H
    Front Physiol; 2017; 8():508. PubMed ID: 28769820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toll like receptor signaling in "inflammaging": microRNA as new players.
    Olivieri F; Rippo MR; Prattichizzo F; Babini L; Graciotti L; Recchioni R; Procopio AD
    Immun Ageing; 2013 Mar; 10(1):11. PubMed ID: 23506673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toll-like receptors, their ligands, and atherosclerosis.
    Hodgkinson CP; Ye S
    ScientificWorldJournal; 2011 Feb; 11():437-53. PubMed ID: 21336459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toll-like receptors and prostate cancer.
    Zhao S; Zhang Y; Zhang Q; Wang F; Zhang D
    Front Immunol; 2014; 5():352. PubMed ID: 25101092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross talk of the first-line defense TLRs with PI3K/Akt pathway, in preconditioning therapeutic approach.
    Pourrajab F; Yazdi MB; Zarch MB; Zarch MB; Hekmatimoghaddam S
    Mol Cell Ther; 2015; 3():4. PubMed ID: 26056605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.